Kristine Peterson net worth and biography

Kristine Peterson Biography and Net Worth

Director of ImmunoGen

Kristine Peterson has served as director of ImmunoGen since 2012. Ms. Peterson served as Chief Executive Officer of Valeritas, Inc. from 2009-2016. Prior to that she served as Company Group Chair of Johnson & Johnson’s biotech groups from 2006 to 2009, and as Executive Vice President for J&J’s global strategic marketing organization from 2004 to 2006. Prior to that she served as Senior Vice President, Commercial Operations for Biovail Corporation and President of Biovail Pharmaceuticals from 2003 to 2004. Prior to that she spent 20 years at Bristol-Myers Squibb Company in assignments of increasing responsibility spanning marketing, sales and general management, including running a cardiovascular/metabolic business unit and a generics division. Ms. Peterson is also a director of Amarin Corporation plc and Paratek Pharmaceuticals, Inc.

How do I contact Kristine Peterson?: The corporate mailing address for Ms. Peterson and other ImmunoGen executives is 830 WINTER ST, WALTHAM MA, 02451. ImmunoGen can also be reached via phone at (781) 895-0600 and via email at courtney.okonek@immunogen.com. Learn More on Kristine Peterson's contact information.
Has Kristine Peterson been buying or selling shares of ImmunoGen?: Kristine Peterson has not been actively trading shares of ImmunoGen within the last three months. Most recently, Kristine Peterson sold 20,000 shares of the business's stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $28.90, for a transaction totalling $578,000.00. Learn More on Kristine Peterson's trading history.
Who are ImmunoGen's active insiders?: ImmunoGen's insider roster includes Susan Altschuller (Sr. VP & CFO ), Stacy Coen (SVP), Mark Enyedy (President, CEO & Director), Mark Enyedy (CEO), Renee Lentini (Insider), Kristine Peterson (Director), and Theresa Wingrove (SVP). Learn More on ImmunoGen's active insiders.

Kristine Peterson Insider Trading History at ImmunoGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/30/2023	Sell	20,000	$28.90	$578,000.00

Kristine Peterson Buying and Selling Activity at ImmunoGen

ImmunoGen Company Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Today's Range

Now: N/A

50 Day Range

MA: $31.23

$31.23

2 Week Range

Now: N/A

Volume

40 shs

Average Volume

8,778,325 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield